Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052581) VECTORS AND METHODS FOR IMMUNIZATION OR THERAPEUTIC PROTOCOLS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052581 International Application No.: PCT/US1998/010408
Publication Date: 26.11.1998 International Filing Date: 20.05.1998
Chapter 2 Demand Filed: 21.12.1998
IPC:
A61K 39/29 (2006.01) ,A61K 39/39 (2006.01) ,A61K 48/00 (2006.01) ,C12N 15/861 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
29
Hepatitis virus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79
Vectors or expression systems specially adapted for eukaryotic hosts
85
for animal cells
86
Viral vectors
861
Adenoviral vectors
Applicants:
OTTAWA CIVIC HOSPITAL LOEB RESEARCH INSTITUTE [CA/CA]; 725 Parkdale Avenue Ottawa, Ontario K1Y 4E9, CA (AllExceptUS)
UNIVERSITY OF IOWA RESEARCH FOUNDATION [US/US]; 214 Technology Innovation Center Oakdale Research Campus Iowa City, IA 52242, US (AllExceptUS)
QIAGEN GMBH [DE/DE]; Max-Vomer-Strasse 4 D-40721 Hilden, DE (AllExceptUS)
DAVIS, Heather, L. [CA/CA]; CA (UsOnly)
KRIEG, Arthur, M. [US/US]; US (UsOnly)
SCHORR, Joachim [DE/DE]; DE (UsOnly)
WU, Tong [CA/CA]; CA (UsOnly)
Inventors:
DAVIS, Heather, L.; CA
KRIEG, Arthur, M.; US
SCHORR, Joachim; DE
WU, Tong; CA
Agent:
LOCKHART, Helen, C.; Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue Boston, MA 02210, US
Priority Data:
60/047,20920.05.1997US
60/047,23320.05.1997US
Title (EN) VECTORS AND METHODS FOR IMMUNIZATION OR THERAPEUTIC PROTOCOLS
(FR) VECTEURS ET PROCEDES DESTINES A L'IMMUNISATION ET A DES PROTOCOLES THERAPEUTIQUES
Abstract:
(EN) The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.
(FR) La présente invention concerne l'amélioration des vecteurs de vaccin d'ADN par élimination de motifs CpG-N et addition éventuelle de motifs CpG-S. En outre, dans le cas de niveaux d'expression élevés et durables, le vecteur optimisé inclut un promoteur/renforçateur qui n'est pas rétro-régulé par les cytokines induites par les motifs CpG immunostimulateurs. L'invention concerne également des vecteurs et des procédés d'immunostimulation. L'invention concerne, en outre, l'amélioration des vecteurs de thérapie génique consistant à déterminer les motifs CpG-N et CpG-S présents dans le produit de recombinaison, à éliminer des motifs stimulateurs CpG(CpG-S) et/ou à insérer des motifs neutralisant CpG(CpG-N), de façon à obtenir un produit de recombinaison d'acide nucléique assurant une expression améliorée du polypeptide thérapeutique. L'invention concerne des procédés de fabrication des vecteurs précités.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1003531CA2301575AU1998076908